News|Articles|June 18, 2026

Familiar Faces at Revolutionizing Atopic Dermatitis 2026

Author(s)Marie Bosslett, Assistant Editor

Listen

0:00 / 0:00

Key Takeaways

Subscribing to eNewsletters provides a direct, curated channel for receiving conference-related insights on a recurring cadence.
Following social media accounts supports real-time awareness of updates and announcements as new information is released.
Combining inbox delivery with social feeds reduces the need for manual searching while maintaining continuity of information flow.

As RAD kicks off in Nashville, Tennessee, scroll through and find some faces familiar to Dermatology Times who are presenting at the meeting.

To stay up-to-date with the latest conference insights, sign up to receive our eNewsletters and follow us on social media.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related to this article

October 9th, 2026

Day 2 Recap: Fall Clinical 2026

The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.

October 9th, 2026

No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis

No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.

October 9th, 2026

Nemolizumab Maintains Deep Skin and Itch Responses Through 3 Years in Atopic Dermatitis

Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.

October 9th, 2026

Icotrokinra Maintains Skin Clearance Through 2 Years in Phase 3 ICONIC-LEAD

At week 112, at least 72% of patients on icotrokinra held PASI 90 and at least 44% held PASI 100, with no new safety signals reported.

October 8th, 2026

Upadacitinib Shows Broader Inflammatory Effects and Earlier Skin Barrier Restoration Than Dupilumab in Atopic Dermatitis

Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.

October 8th, 2026

Previewing the 2026 Fall Clinical Dermatology Conference

The 4-day CME meeting in Las Vegas offers up to 24.25 credits and sessions on inflammatory skin disease, skin cancer, pediatric dermatology, aesthetics, and more.

October 7th, 2026

Abrocitinib Reduces Pathogenic Skin-Resident Memory T Cells in Atopic Dermatitis

A biopsy-based analysis from the JADE MOA trial presented at EADV 2026 found reductions in pathogenic skin-resident memory T cells alongside restoration of epidermal barrier integrity.

October 6th, 2026

Dermatology Times Conferences & Meetings Calendar: October 2026

Explore dermatology conferences and meetings taking place this October, including clinical updates, skin of color education, and pediatric dermatology research.

Familiar Faces at Revolutionizing Atopic Dermatitis 2026

Key Takeaways

Related to this article

Trending on Dermatology Times

Ixekizumab Plus Tirzepatide Shifts Biomarkers in Psoriasis with Obesity

Nemolizumab Maintains Deep Skin and Itch Responses Through 3 Years in Atopic Dermatitis

No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis

Upadacitinib Shows Broader Inflammatory Effects and Earlier Skin Barrier Restoration Than Dupilumab in Atopic Dermatitis

Icotrokinra Maintains Skin Clearance Through 2 Years in Phase 3 ICONIC-LEAD